Advertisement
ICU vs UNCY
Which Stock Would AI Choose? SeaStar Medical Holding (ICU) vs. Unicycive Therapeutics (UNCY) Stock Comparison
Key Takeaways
- Both ICU and UNCY are micro-cap healthcare companies focused on kidney-related conditions, yet they sit at different stages: ICU is commercial-stage with an FDA-approved device, while UNCY is clinical-stage with a lead drug candidate still under review.
- ICU (SeaStar Medical) has generated revenue from its QUELIMMUNE device but remains deeply unprofitable, while UNCY (Unicycive Therapeutics) is effectively pre-revenue and dependent on a single regulatory catalyst.
- UNCY's near-term story revolves around a resubmitted New Drug Application (NDA) and a new FDA decision date, whereas ICU's narrative centers on clinical enrollment, breakthrough designation, and commercialization momentum.
- Relative performance has diverged sharply in recent weeks: both stocks have pulled back from earlier highs, but UNCY's larger cash balance and higher volatility profile distinguish its risk-reward setup.
- Market positioning favors UNCY on balance-sheet strength and defined catalysts, while ICU offers an approved product but carries meaningful dilution and funding risks.
- Readers can find more details on each name's headlines and intraday action: ICU Major News and ICU Today's Price Move, plus UNCY Major News and UNCY Today's Price Move.
- For automated, data-driven trading ideas across the market, explore Trending AI Robots.
Introduction
This stock comparison examines two small-cap healthcare companies that share a therapeutic focus on kidney disease but operate under very different business models. SeaStar Medical Holding (ICU) is a commercial-stage medical-device developer, while Unicycive Therapeutics (UNCY) is a clinical-stage biotechnology firm awaiting a regulatory decision. For traders and investors, the contrast is instructive: one name offers an approved product with early revenue, while the other offers a larger cash cushion and a clearly defined binary catalyst. Understanding how their relative performance, market positioning, and risk profiles differ can help both momentum-focused traders and longer-horizon healthcare investors evaluate which opportunity better suits their approach in the current environment.
ICU Overview and Recent Performance
SeaStar Medical Holding Corporation (ICU) develops a platform therapy designed to reduce hyperinflammation affecting vital organs. Its core technology is the Selective Cytopheretic Device (SCD), which aims to neutralize overactive immune cells, and its first commercial product, QUELIMMUNE, is FDA-approved for pediatric patients with acute kidney injury (AKI) caused by sepsis. The company is also advancing NEUTRALIZE-AKI, a pivotal trial in adult patients with AKI.
Recent market activity has been mixed. The stock has pulled back notably over recent weeks after trading well above current levels earlier in the year, reflecting the volatility typical of micro-cap medical-device names. Positive developments have included a Breakthrough Device Designation from the FDA for the SCD in adults with sepsis, along with late-breaking survival data presented at a major nephrology conference. Offsetting these catalysts, the company has a limited cash position and has relied on warrant exercises and financing to fund operations, contributing to shareholder dilution. Revenue remains modest relative to the company's valuation, and profitability is still distant.
UNCY Overview and Recent Performance
Unicycive Therapeutics (UNCY) is a clinical-stage biotechnology company developing treatments for kidney disease. Its lead candidate, oxylanthanum carbonate (OLC), is an oral phosphate binder for hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis, designed to reduce pill burden versus existing therapies. A second candidate, UNI-494, targets acute kidney injury and holds orphan drug designation for the prevention of delayed graft function in kidney transplant patients.
Recent performance has been driven almost entirely by regulatory news. The company's OLC application has faced two Complete Response Letters (CRLs) tied to third-party manufacturing deficiencies rather than clinical or safety concerns. In recent weeks, the FDA accepted a resubmitted NDA and set a new Prescription Drug User Fee Act (PDUFA) target action date in early 2027, using data from a new manufacturing vendor. This news briefly lifted shares, but the stock remains well below its levels from earlier in the year and carries elevated short interest. A sizable cash balance provides a longer runway relative to peers, though the company is pre-revenue and has also experienced meaningful share-count growth.
Trending AI Robots
For traders seeking a more systematic approach to market volatility, Tickeron's Trending AI Robots page offers a curated selection of automated trading strategies. Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and statistical profile. Rather than listing every available bot, the Trending AI Robots section highlights only those judged most suitable for current market conditions, helping users cut through the noise. Because each bot differs in risk tolerance, holding period, and the set of tickers it trades, the platform lets investors evaluate options that align with their individual objectives. Explore the Trending AI Robots page to review currently featured strategies.
Head-to-Head Comparison
The most important contrast between these two names is stage of development. ICU is commercial-stage with an approved product and early revenue, whereas UNCY is pre-revenue and hinges on regulatory approval. This translates into different growth drivers: ICU's upside depends on expanding QUELIMMUNE adoption and progressing the adult AKI trial, while UNCY's near-term value is concentrated in a single FDA decision date.
Risk factors also differ. ICU carries a thinner cash cushion and a history of dilutive financing, which has pressured the share price. UNCY holds a substantially larger cash position, but its elevated beta and high short interest signal greater price volatility, and its approval timeline remains dependent on manufacturing inspections outside the company's control. On sector exposure, both sit within healthcare and kidney disease, yet ICU is classified more as a medical-device business while UNCY is a pharmaceutical developer. Market sentiment toward both has cooled from prior highs, but UNCY's defined binary catalyst gives it a more event-driven profile, whereas ICU's outlook depends on slower, execution-driven commercial progress.
Tickeron AI Verdict
Based on observable factors such as balance-sheet strength, catalyst clarity, and relative positioning, Tickeron's AI would likely view UNCY as the comparatively more attractive near-term setup. The company's larger cash reserve provides a longer operational runway, and a newly established PDUFA date offers a specific, datable catalyst that algorithmic models can weight. ICU, by contrast, offers an approved product and genuine commercial progress but is constrained by a thinner cash position, dilution risk, and a more execution-dependent outlook. This assessment is probabilistic rather than definitive: both stocks carry elevated risk, and the relative appeal of each can shift quickly with new clinical, regulatory, or financing developments. Traders should weigh these factors against their own time horizon and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICU is a Hold and UNCY is a StrongBuy.
ICU sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ICU moved below the 200-day moving average on October 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ICU moved out of overbought territory on October 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 19 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICU as a result. In 76 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for ICU turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
ICU moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ICU crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ICU entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICU advanced for three days, in 150 of 183 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ICU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.247) is normal, around the industry mean (3.104). P/E Ratio (-1.159) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (6.468) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ICU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
UNCY in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 02, 2026
UNCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where UNCY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where UNCY's RSI Oscillator exited the oversold zone, 29 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 73 cases where UNCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for UNCY just turned positive on October 22, 2026. Looking at past instances where UNCY's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
Following a +5.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNCY advanced for three days, in 209 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNCY as a result. In 91 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for UNCY entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.825) is normal, around the industry mean (3.104). P/E Ratio (-1.994) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (39.216) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. UNCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| ICU | UNCY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 70% | 1 day ago 83% |
| Stochastic ODDS (%) | 1 day ago 74% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| Advances ODDS (%) | 8 days ago 82% | 6 days ago 83% |
| Declines ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 87% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ICU’s FA Score shows that 1 FA rating(s) are green while UNCY’s FA Score has 1 green FA rating(s).
- ICU’s FA Score: 1 green, 4 red.
- UNCY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ICU’s TA Score shows that 3 TA indicator(s) are bullish while UNCY’s TA Score has 5 bullish TA indicator(s).
- ICU’s TA Score: 3 bullish, 8 bearish.
- UNCY’s TA Score: 5 bullish, 3 bearish.
Price Growth
ICU (@Biotechnology) experienced а -11.34% price change this week, while UNCY (@Biotechnology) price change was -2.51% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.92%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -20.21%.
Reported Earning Dates
ICU is expected to report earnings on Nov 12, 2026.
UNCY is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-0.92% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ICU and
Correlation & Price change
A.I.dvisor indicates that over the last year, ICU has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if ICU jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To ICU | 1D Price Change % | ||
|---|---|---|---|---|
| ICU | 100% | -2.23% | ||
| CANF - ICU | 93% Closely correlated | +0.62% | ||
| APVO - ICU | 85% Closely correlated | N/A | ||
| GNPX - ICU | 82% Closely correlated | -0.45% | ||
| TNXP - ICU | 77% Closely correlated | +0.98% | ||
| LONA - ICU | 62% Loosely correlated | -4.25% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BIDD | 28.87 | 0.13 | +0.44% |
| iShares International Dividend Active ETF (BIDD) | |||
| CCOM | 25.99 | N/A | N/A |
| Simplify Chinese Commodities Strategy No K-1 ETF (CCOM) | |||
| KBAB | 6.45 | N/A | N/A |
| KraneShares 2x Long BABA Daily ETF (KBAB) | |||
| FLKR | 49.99 | -0.43 | -0.85% |
| Franklin FTSE South Korea ETF (FLKR) | |||
| NRSH | 28.86 | -0.70 | -2.38% |
| Aztlan North America Nearshoring Stock Selection ETF (NRSH) | |||